Literature DB >> 14980665

Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2.

Denis Riendeau1, Myriam Salem, Angela Styhler, Marc Ouellet, Joseph A Mancini, Chun Sing Li.   

Abstract

Loxoprofen, its trans-alcohol and cis-alcohol metabolites were evaluated for selectivity of inhibition of COX-2 over COX-1. The (2S,1'R,2'S)-trans-alcohol derivative was found to be the most active metabolite and to be a potent and nonselective inhibitor of COX-2 and COX-1 in both enzyme and human whole blood assays.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980665     DOI: 10.1016/j.bmcl.2003.12.047

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Authors:  Adolfo Quiñones-Lombraña; Nasi Li; Virginia Del Solar; G Ekin Atilla-Gokcumen; Javier G Blanco
Journal:  Biopharm Drug Dispos       Date:  2018-06       Impact factor: 1.627

2.  Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain.

Authors:  Pierre-Olivier Hétu; Denis Riendeau
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

3.  Loxoprofen Sodium Alleviates Oxidative Stress and Apoptosis Induced by Angiotensin II in Human Umbilical Vein Endothelial Cells (HUVECs).

Authors:  Chuanzhao Ji; Yang Yu; Min Zhang; Wenyan Yu; Shuo Dong
Journal:  Drug Des Devel Ther       Date:  2020-11-18       Impact factor: 4.162

4.  Solubility Optimization of Loxoprofen as a Nonsteroidal Anti-Inflammatory Drug: Statistical Modeling and Optimization.

Authors:  Mohammed Alqarni; Nader Ibrahim Namazi; Sameer Alshehri; Ibrahim A Naguib; Amal M Alsubaiyel; Kumar Venkatesan; Eman Mohamed Elmokadem; Mahboubeh Pishnamazi; Mohammed A S Abourehab
Journal:  Molecules       Date:  2022-07-07       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.